A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safety/Tolerability/Efficacy of Oral Gefitinib 250 mg Versus IV Docetaxel 60 mg/m2 in Patients With Locally Advanced or Metastatic NSCL Cancer of Adenocarcinoma Histology Previous Treated With One Platinum Base Chemotherapy
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary objective of this study is to compare safety and tolerability between gefitinib and docetaxel
time to disease progression
No
Han-Pin Kuo, MD
Principal Investigator
Director of Chest Department, Chang Gung Memorial Hospital, Linkou
Taiwan: Department of Health
D7913C00046
NCT00536107
October 2007
August 2009
Name | Location |
---|